Lack of promoting effects of phenobarbital at low dose on diethylnitrosamine-induced hepatocarcinogenesis in TGF-alpha transgenic mice.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Kang, Jin Seok
Salim, Elsayed I.
Merlino, Glenn T.
MetadataShow full item record
AbstractPhenobarbital (PB), a rodent non-genotoxic carcinogen, showed hormesis, biphasic effects on rat liver carcinogenesis. To test the hypothesis that the hormesis earlier observed for PB induced hepatocarcinogenesis might also exist in the TGF-alpha transgenic mice model, one which is highly susceptible to carcinogenesis, the carcinogenic or promotion effects of a wide range of phenobarbital (PB) concentrations were investigated. Two weeks after a single i.p. dose of 5 mg /kg bw of diethylnitrosamine (DEN) to 15 day old mice, animals were treated with diet containing PB at doses of 0, 2, 15 or 500 ppm. The incidence and multiplicity of tumors, including hepatocellular adenomas and carcinomas, were significantly increased by the high dose of PB, but no significant difference among the groups receiving 2 and 15 ppm for liver tumors when compared to DEN alone group. The proliferating cell nuclear antigen indices for liver tumors and surrounding hepatocytes in high dose PB treated mice were significantly increased, but no change was noted at the lower doses. The total cytochrome P450 content in the liver was also elevated by 500 ppm of PB, while hepatic 8-OHdG levels demonstrated no significant change. In conclusion, PB at high dose enhances DEN-induced hepatocarcinogenesis in TGF-alpha transgenic mice, but low doses lack any significant effects. One possible mechanism of phenobarbital carcinogenicity might be influenced by cytochrome P450 system exhibiting a strong promoting activity for liver of mice.
CitationAsian Pac. J. Cancer Prev. 2006, 7 (2):274-278
DescriptionKEYWORDS-CLASSIFICATION: administration & dosage;Animals;Anticonvulsants;Carcinogenicity Tests;Carcinogens;chemically induced;Diethylnitrosamine;Dose-Response Relationship,Drug;genetics;Japan;Liver Neoplasms;mechanisms of carcinogenesis;metabolism;Mice;Mice,Transgenic;pathology;Phenobarbital;Research;toxicity;Transforming Growth Factor alpha;
- Rapid development of hepatic tumors in transforming growth factor alpha transgenic mice associated with increased cell proliferation in precancerous hepatocellular lesions initiated by N-nitrosodiethylamine and promoted by phenobarbital.
- Authors: Tamano S, Merlino GT, Ward JM
- Issue date: 1994 Sep
- Enhancement of N-nitrosodiethylamine-initiated hepatocarcinogenesis by phentoin in male F344/NCr rats at a dose causing maximal induction of CYP2B.
- Authors: Diwan BA, Henneman JR, Nims RW
- Issue date: 2001 Mar-Apr
- Presence of a threshold for promoting effects of phenobarbital on diethylnitrosamine-induced hepatic foci in the rat.
- Authors: Kitano M, Ichihara T, Matsuda T, Wanibuchi H, Tamano S, Hagiwara A, Imaoka S, Funae Y, Shirai T, Fukushima S
- Issue date: 1998 Aug
- Sodium phenobarbital-enhanced mutation frequency in the liver DNA of lacZ transgenic mice treated with diethylnitrosamine.
- Authors: Okada N, Honda A, Kawabata M, Yajima N
- Issue date: 1997 May
- Dissimilar patterns of promotion by di(2-ethylhexyl)phthalate and phenobarbital of hepatocellular neoplasia initiated by diethylnitrosamine in B6C3F1 mice.
- Authors: Ward JM, Rice JM, Creasia D, Lynch P, Riggs C
- Issue date: 1983 Aug